Stocks
Reata Pharmaceuticals, Inc.RETA
NASDAQHealthcareBiotechnology$172.36+0.02%
Focused on developing novel therapeutics for severe and life-threatening diseases, this biopharmaceutical company has gained investor attention for its FDA-approved treatment for Friedreich's ataxia. Its pipeline targets mitochondrial and oxidative stress-related conditions, making it a key player in rare disease therapeutics.
Market Cap: $6.6B52W Range: $21.83 – $172.46
Congressional Interest in Reata Pharmaceuticals, Inc. (RETA)
2 members of Congress have disclosed 3 trades in Reata Pharmaceuticals, Inc. (RETA), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
2
Sells
1
Who in Congress Is Trading RETA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-04 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-12-28 | Christopher L. Jacobs | buy | $1K – $15K |